Format

Send to

Choose Destination
Clin Liver Dis. 2003 Feb;7(1):149-61.

Current therapy for hepatitis C: pegylated interferon and ribavirin.

Author information

1
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Abstract

The combinations of peginterferon alfa-2a or peginterferon alfa-2b with ribavirin lead to significant improvement in sustained virological response when compared with standard interferon and ribavirin therapy. These newer agents represent the most effective treatments available for the initial therapy of patients with chronic hepatitis C. A review of the clinical trials to date suggests certain similarities and differences between the two preparations. For both regimens, however, it is apparent that information concerning the predictability of response and the importance of adherence to the treatment regimens will be of great value in the therapeutic management of chronic hepatitis C. Although viral load and genotype, gender, age, and absence of fibrosis have been shown consistently to be important predictors of response, identification of additional host immune and genetic factors involved in determining outcome of antiviral therapy are necessary.

PMID:
12691464
DOI:
10.1016/s1089-3261(02)00077-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center